Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

Breast Cancer Clinical Trial

Official title:

Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06015126
• Other study ID #: Y-pierrefabre202102-0108
• Status: Recruiting
• Phase: N/A
• Start date: October 5, 2022
• Est. completion date: January 2026

Study information

• Verified date: August 2023
• Source: Xi'an International Medical Center Hospital
• Contact: Yan Xue
• Phone: 0086-13992830596
• Email: 1410605462[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

vinorelbine are one of the main chemotherapy drugs used in the treatment of advanced breast cancer. It is available in oral form, making it convenient to use and an ideal choice for rhythmic chemotherapy. In advanced breast cancer,metronomic oral vinorelbine chemotherapy has been the subject of several clinical studies, with proven effectiveness and good safety, showing great prospects for application. Considering the current lack of targeted, efficient, and convenient drugs for HER2-negative advanced breast cancer in later lines of treatment, and based on the preliminary efficacy of metronomic oral vinorelbine, anlotinib, and rhythmic chemotherapy in breast cancer, we plan to explore the efficacy and safety of combining metronomic oral vinorelbine chemotherapy with anlotinib in the treatment of HER2-negative advanced breast cancer, providing new data for the treatment of HER2-negative advanced breast cancer.

Description:

Research Title A single-center, open-label, single-arm clinical study on the efficacy and safety of Changchun Ruibin rhythmic chemotherapy combined with anlotinib in HER2-negative advanced breast cancer. Study Drugs - metronomic oral vinorelbine: 30mg/capsule, 20mg/capsule - Anlotinib: 12mg/capsule, 10mg/capsule, 8mg/capsule Research Objective To determine the efficacy and safety of metronomic oral vinorelbine chemotherapy combined with anlotinib in the treatment of HER2-negative advanced breast cancer, and to provide new data for later-line treatment of HER2-negative advanced breast cancer. Study Design A single-center, open-label, single-arm clinical study with a planned enrollment of 60 patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: January 2026
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Voluntarily sign an informed consent form;
• Females aged 18 years or older;
• ECOG physical performance status score of 0-2;
• Histologically confirmed HER2-negative metastatic breast cancer patients, and patients with locally recurrent disease who cannot undergo curative surgery or radiation therapy;
• HR-positive/HER2-negative advanced breast cancer patients who have primary endocrine resistance or disease progression after first-line endocrine ± targeted therapy;
• Triple-negative advanced breast cancer patients with disease progression after first-line chemotherapy ± immunotherapy;
• Blood routine examination meets the following conditions: ?absolute neutrophil count (ANC) =1.5×10^9/L, ? platelets =100×10^9/L, ? hemoglobin =90 g/L, ? white blood cell count =3.0×10^9/L;
• The liver function meets the following criteria: ? serum total bilirubin = 1.5 × ULN, and if there is liver metastasis, it should be = 3 × ULN; ? AST or ALT = 3 × ULN, and if there is liver metastasis, it should be = 5 × ULN;
• The renal function meets the following criteria: serum creatinine = 1.5 × ULN or creatinine clearance = 50 mL/min (calculated according to the Cockroft-Gault formula);
• Female patients who meet the following criteria can participate in this study: ? Patients are not capable of reproduction; ? Patients have reproductive capacity, and have a negative result on the pregnancy test within 7 days before the first administration of the investigational drug, are not in the lactation period, and continuously adopt effective contraceptive measures before entering the study and during the entire study period and within 6 months after the last administration of the investigational drug.

Exclusion Criteria:

• Patients who have previously received treatment with vinorelbine and/or anlotinib;
• Patients with active or untreated brain metastasis;
• Patients who have had or currently have other malignancies within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invades basement membrane)];
• Patients who have undergone major surgery (including thoracotomy biopsy) or suffered a significant trauma (such as bone fracture) within 4 weeks before randomization, have unhealed wounds or fractures at the time of screening, or are expected to undergo major surgery during the study period;
• Patients with a history of myocardial infarction within the past 6 months; history of congestive heart failure with New York Heart Association (NYHA) classification = II, or severe arrhythmia (excluding atrial fibrillation and paroxysmal supraventricular tachycardia) that cannot be controlled by medication;
• Patients with known allergies to the drugs and their excipients involved in this trial;
• Patients with a known history of hypersensitivity reactions to any investigational drugs;
• Patients who are simultaneously participating in other trials;
• Patients who cannot evaluate the efficacy of the treatment plan with existing technology;
• Patients judged unsuitable for participation by other investigators.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• metronomic oral vinorelbine plus anlotinib
To clarify the efficacy and safety of metronomic oral vinorelbine plus anlotinib in HER2-negative metastatic breast cancer patients, adding new data for the posterior treatment of HER2-negative advanced breast cancer

Locations

Country	Name	City	State
China	Xi'an International Medical Center Hospital	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
Yan Xue

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival	It is an indicator of the long-term efficacy of the drug.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Secondary	Objective Response Rate	The proportion of patients with the best response of complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST).	4 weeks
Secondary	Disease Control Rate	The proportion of patients with tumor shrinkage or stability maintained for a certain period, including cases of CR, PR, and stable disease (SD).	4 weeks
Secondary	Overall survival	It is an indicator of the long-term efficacy of the drug.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months